Browse the evidence

The global prevalence of obesity has risen sharply during the past half-century, reaching pandemic proportions.

Clinicians should be aware of the increasing obesity rates as a public health concern.

Conventional drug therapies explored in OSA have generally produced disappointing results.

Practitioners should be aware that current drug therapies for OSA may not be effective.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.

There were no effects on diet quality for the 'tax' and 'healthier substitute offers.'

Strategies such as taxing unhealthy foods and offering healthier substitutes may not improve diet quality.

There is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.

Clinicians should be cautious and consider FDA approval status when prescribing incretin analogs.

Approximately 10% of obesity-related glomerulopathy (ORG) patients progress to end stage renal disease 6.2 years after diagnosis.

Healthcare providers should monitor ORG patients closely for progression to end stage renal disease.

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

There were no significant between-group differences in VAT volume after 6 months or 12 months.

Dietary interventions may not differ significantly in their effects on VAT volume over time.

Demographics associated with higher prescription period prevalence included non-Hispanic Black race and ethnicity, female sex, and older age.

Understanding these demographic factors can help tailor interventions and support for specific groups.

Semaglutide is available in two formulations: once-weekly subcutaneous and once-daily oral.

Practitioners can offer patients a choice between two formulations of semaglutide for weight management.

Only 8% of eligible candidates with type 2 diabetes are prescribed GLP-1RA.

Cardiologists should be aware of the low prescription rates of GLP-1RA among eligible patients.

The uptake of GLP-1RA in clinical practice is low among cardiologists.

Efforts are needed to increase awareness and education among cardiologists regarding GLP-1RA.

If 1%, 5%, or 10% of the population aged 60 years or older is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.

Understanding these cost projections is crucial for policymakers and healthcare planners.

Concerns regarding operative risks, irreversibility, and excess costs limit the broader clinical use of metabolic and bariatric surgeries.

Practitioners should be aware of these concerns when discussing surgical options with patients.

Rates of early termination of EGD were similar between groups.

Practitioners can expect similar rates of early termination of EGD regardless of GLP-1RA continuation.

There were no aspiration events in either group.

Practitioners can be reassured that there is no increased risk of aspiration events with GLP-1RA use during EGD.

Body mass index (BMI) requirements for gender-affirming surgeries (GAS) present an obstacle to gender transition for many transgender and gender diverse (TGD) people.

Clinicians should be aware of the BMI-related barriers faced by TGD patients when considering GAS.

There is limited evidence supporting the effectiveness of n-3-PUFA supplementation in improving or preventing loss of lean mass in both younger and older healthy adults, as well as clinical populations including oncologic patients.

Practitioners should be cautious in recommending n-3-PUFA supplementation for lean mass improvement.

Most systematic reviews concluded that n-3-PUFA supplementation did not significantly affect strength.

Strength training recommendations should not rely on n-3-PUFA supplementation.

There was no consistent impact of n-3-PUFA supplementation on functional outcome measures.

Functional improvements should not be expected from n-3-PUFA supplementation.

No statistically significant associations were identified for SGLT2 inhibitors regarding hematologic malignancy risk.

SGLT2 inhibitors may not pose a risk for hematologic malignancies, making them a safer choice in this regard.

Up to 40% of adults in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD).

Practitioners should be aware of the high prevalence of MASLD in adult patients.

Metabolic dysfunction-associated steatohepatitis is now a leading indication for liver transplantation.

Healthcare providers should consider MASLD as a critical factor in liver transplant evaluations.